Michal Štícha

Cardiovascular risk among smokers seeking cessation treatmentcompared to smokers who do not: A cross-sectional study

Kamila Zvolská, Eva Králíková, Alexandra Kmeťová, Lenka Štěpánková et autres

Objectives: To compare the cardiovascular (CV) risk profile in smokers who decided to quit in smoking cessation center (Center) and smokers of general population. Methods: We retrospectively compared the prevalence of CV risk factors and theCV risk level in a study group …

Factors associated with weight changes in successful quitters participating in a smoking cessation program

Alexandra Kmeťová, Eva Králíková, Lenka Štěpánková, Kamila Zvolská et autres

cz, us (code pays fourni par la source)

Tobacco Treatment Outcomes in Patients With and Without a History of Depression, Czech Republic, 2005–2010

Lenka Štěpánková, Eva Králíková, Kamila Zvolská, Alexandra Kmeťová et autres

INTRODUCTION: Higher prevalence of smoking among depressed patients, as well as the risk of depression in smokers, is well documented. The proportion of patients with a history of depression among those seeking intensive treatment of tobacco dependence is also high. In contrast, …

cz, us (code pays fourni par la source)

A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice

Vı́tězslav Kolek, Miloš Pešek, Ivona Grygárková, Petr Zatloukal et autres

cz (code pays fourni par la source)

The role of a center for tobacco-dependent in cardiovascular prevention. A retrospective study.

Kamila Zvolská, Eva Králíková, Alexandra Kmeťová, Lenka Štěpánková et autres

OBJECTIVES: Smoking cessation is an essential part of cardiovascular disease (CVD) prevention. At the Center for Tobacco-Dependent (CTD), clients are screened to identify and reduce cardiovascular (CV) risk factors. In our study we have focused on the role of the CTD in …

cz (code pays fourni par la source)

Paliativní chemoterapie karcinomu žaludku - update vlastníhosouboru.

Radka Lordick Obermannova, Jiří Navrátil, Rostislav Vyzula, Michal Štícha

Pemetrexed in the Second Line Chemotherapy of Non-small Cell Lung Cancer. A Multicentre Prospective Analysis of Data From Clinical Practice

Vı́tězslav Kolek, Jaromı́r Roubec, Miloš Pešek, Ivona Grygárková et autres

cz (code pays fourni par la source)

Erlotinib (Tarceva) in the treatment of non-selected populationof 1735 patients with advaced non-small-cell lung cancer(NSCLC) from Czech Republic

Jana Skřičková, Miloš Pešek, Pavel Zatloukal, Vı́tězslav Kolek et autres

The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.

Zkušenosti s používáním lapatinibu v léčbě karcinomu prsu vČeské republice

Lubomír Slavíček, V. Benešová, Michal Štícha, Ladislav Dušek

Pemetrexed in the firs line chemotherapy of malignantpleuralmesotelioma. A multicentre prospective study

Vı́tězslav Kolek, Pavel Zatloukal, Miloš Pešek, František Salajka et autres

Malignant pleural mesothelioma (MPM) is a tumour with extremely unfavourable prognosis. Early diagnostic is rarely possible and chemotherapy has only a limited value in prolongation of survival. During the last years pemetrexed became the standard 1st line chemotherapy.

The analysis of influence of clinical predictors on the resultsof treatment with erlotinib in patients with advanced non-smallcell lung cancer.

František Salajka, Miloš Pešek, Jana Krejčí, Jana Skřičková et autres

Erlotinib is a tyrosine-kinase inhibitor (TKI) used for the treatment of patients with non small cell lung cancer (NSCLC) in Czech Republic since 2005. Wide use of erlotinib in patients with NSCLC enables to collect a robust data in Czech Tarceva patients …

Klinické zkušenosti s léčbou erlotinibem u nemocných s pokročilým nemalobuněčným bronchogenním karcinomem

Marcela Tomíšková, Jana Skřičková, Michal Štícha

Erlotinib patři v soucasnosti k peroralnim nizkomolekularnim inhibitorům tyrozinkinazove aktivity, který je v Ceske republice již několik let použivan v lecbě pokrocileho nemalobuněcneho karcinomu (NSCLC) napřic vsemi liniemi. Kromě teoretických poznatků týkajicich se mechanizmu ucinku jednoho z leků cilene biologicke lecby se …